Update: chronisch entzündliche Darmerkrankungen

Zusammenfassung

Morbus Crohn (MC) und Colitis ulcerosa (CU) stellen die beiden Hauptformen der chronisch entzündlichen Darmerkrankungen (CED) dar. Die CED sind klinische Diagnosen, welche durch zusätzliche endoskopische, histologische, radiologische, sonographische und laborchemische Untersuchungs-befunde ergänzt werden. Die CED sind nicht nur auf den GI-Trakt beschränkt, sondern es handelt sich um Systemerkrankungen, welche häufig auch extra-intestinale Manifestationen aufweist. Grundlegendes Behandlungsziel in der medikamentösen Therapie von CED ist die Induktion und dauerhafte Erhaltung einer steroidfreien Remission. Abhängig von der Schwere, der Krankheitsaktivität, dem Befallsmuster und dem bisherigen Krankheitsverlauf wird die Therapieentscheidung getroffen. Der natürliche Verlauf der CED kann sich zwischen den Patienten stark unterscheiden und bedingt daher die Notwendigkeit einer individualisierten Therapieentscheidung.

Abstract

Crohn’s disease and ulcerative colitis are the major entities of inflammatory bowel diseases (IBD). IBD is a clinical diagnosis, which is supported by endoscopic, histologic, radiologic, sonographic and laboratory findings. IBD are not restricted to the GI-tract but are instead systemic diseases that often involve extra-intestinal manifestations. Aim of the rational medical therapy is the induction and maintenance of a steroid-free remission. The medical therapy depends on the severity, activity and extent of disease as well as the disease course of the patient. There is the dire necessity for an individualized therapeutic concept as the natural disease course differs between the patients.

Schlüsselwörter

Morbus Crohn - Colitis ulcerosa - Azathioprin - anti-TNF Antikörper

Keywords

Crohn’s disease - ulcerative colitis - azathioprine - anti-TNF antibodies

• Literatur

• 1 Baumgart DC, Sandborn WJ. Crohn’s disease. Lancet 2012; 380: 1590-1605
• 2 Danese S, Fiocchi C. Ulcerative colitis. New Engl J Med 2011; 365: 1713-1725
• 3 Silverberg MS, Satsangi J, Ahmad T et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005; 19 (Suppl. A) : 5-36A
• 4 Ott C, Schölmerich J. Extraintestinal manifestations and complications in IBD. Nat Rev Gastroenterol Hepatol 2013; 10: 585-95
• 5 Preiß JC, Bokemeyer B, Buhr HJ et al. Updated German clinical practice guideline on diagnosis and treatment of crohn’s disease 2014. Z Gastroenterol 2014; 52: 1431-1484
• 6 Dignass A, Preiss JC, Aust DE et al. Updated German guideline on diagnosis and treatment of ulcerative colitis, 2011. Z Gastroenterol 2011; 49: 1276-1341
• 7 Strober W, Fuss I, Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Invest 2007; 117: 514-521
• 8 Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med 2009; 361: 2066-2078
• 9 Knights D, Lassen KG, Xavier RJ. Advances in inflammatory bowel disease pathogenesis: linking host genetics and the microbiome. Gut 2013; 62: 1505-1510
• 10 Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol 2014; 14: 329-342
• 11 Sipponen T. Diagnostics and prognostics of inflammatory bowel disease with fecal neutrophil-derived biomarkers calprotectin and lactoferrin. Dig Dis 2013; 31: 336-344
• 12 Kiesslich R, Fritsch J, Holtmann M et al. Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology 2003; 124: 880-888
• 13 Neurath MF, Travis SP. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut 2012; 61: 1619-1635
• 14 Travis SP, Stange EF, Lémann M et al. European Crohn’s and Colitis Organisation (ECCO). European evidence-based consensus on the management of ulcerative colitis: current management. J Crohns Colitis 2008; 2: 24-62
• 15 Dignass A, Van Assche G, Lindsay JO et al. European Crohn’s and Colitis Organisation (ECCO). The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: current management. J Crohns Colitis 2010; 4: 28-62
• 16 Sandborn WJ, Travis S, Moro L. Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology 2012; 143: 1218-1226
• 17 Travis SP, Danese S, Kupcinskas L et al. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut 2014; 63: 433-441
• 18 Feagan BG, Rutgeerts P, Sands BE et al. GEMINI 1 Study Group. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013; 369: 699-710
• 19 Laharie D, Bourreille A, Branche J et al. Groupe d’Etudes Thérapeutiques des Affections Inflammatoires Digestives. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet 2012; 380: 1909-1915
• 20 Colombel JF, Sandborn WJ, Reinisch W et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med 2010; 362: 1383-1395
• 21 Sandborn WJ, Feagan BG, Rutgeerts P et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 2013; 369: 711-721
• 22 Atreya R, Neumann H, Neufert C et al. In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn’s disease. Nat Med 2014; 20: 313-318